Table of Content

1 Report Overview
1.1 CINV Existing and Pipeline Drugs Definition
1.2 Market by Type
1.2.1 Global CINV Existing and Pipeline Drugs Market Size Growth Rate by Type, 2018 VS 2022 VS 2034
1.2.2 Aloxi
1.2.3 Zofran Generic
1.2.4 Kytril Generic
1.2.5 Emend
1.2.6 Akynzeo
1.2.7 SUSTOL
1.2.8 Rolapitant
1.3 Market Segment by Application
1.3.1 Global CINV Existing and Pipeline Drugs Market Size Growth Rate by Application, 2018 VS 2022 VS 2034
1.3.2 Hospitals
1.3.3 Specialty Clinics
1.3.4 Diagnostic Centers Therapeutics
1.3.5 Hospital Pharmacies
1.3.6 Drugstores
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global CINV Existing and Pipeline Drugs Sales
2.1 Global CINV Existing and Pipeline Drugs Revenue Estimates and Forecasts 2018-2034
2.2 Global CINV Existing and Pipeline Drugs Revenue by Region: 2018 VS 2022 VS 2034
2.3 Global CINV Existing and Pipeline Drugs Revenue by Region
2.3.1 Global CINV Existing and Pipeline Drugs Revenue by Region (2018-2024)
2.3.2 Global CINV Existing and Pipeline Drugs Revenue by Region (2024-2034)
2.4 Global CINV Existing and Pipeline Drugs Sales Quantity Estimates and Forecasts 2018-2034
2.5 Global CINV Existing and Pipeline Drugs Sales Quantity by Region: 2018 VS 2022 VS 2034
2.6 Global CINV Existing and Pipeline Drugs Sales Quantity by Region
2.6.1 Global CINV Existing and Pipeline Drugs Sales Quantity by Region (2018-2024)
2.6.2 Global CINV Existing and Pipeline Drugs Sales Quantity by Region (2024-2034)
2.7 North America
2.8 Europe
2.9 China
2.10 APAC (excluding China)
2.11 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global CINV Existing and Pipeline Drugs Sales Quantity by Manufacturers
3.1.1 Global CINV Existing and Pipeline Drugs Sales Quantity by Manufacturers (2018-2024)
3.1.2 Global CINV Existing and Pipeline Drugs Sales Quantity Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Companies by CINV Existing and Pipeline Drugs Sales in 2022
3.2 Global CINV Existing and Pipeline Drugs Revenue by Manufacturers
3.2.1 Global CINV Existing and Pipeline Drugs Revenue by Manufacturers (2018-2024)
3.2.2 Global CINV Existing and Pipeline Drugs Revenue Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by CINV Existing and Pipeline Drugs Revenue in 2022
3.3 Global CINV Existing and Pipeline Drugs Sales Price by Manufacturers
3.4 Global Key Players of CINV Existing and Pipeline Drugs, Industry Ranking, 2021 VS 2022
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global CINV Existing and Pipeline Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of CINV Existing and Pipeline Drugs, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of CINV Existing and Pipeline Drugs, Product Offered and Application
3.8 Global Key Manufacturers of CINV Existing and Pipeline Drugs, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Estimates and Forecasts by Type
4.1 Global CINV Existing and Pipeline Drugs Sales Quantity by Type
4.1.1 Global CINV Existing and Pipeline Drugs Historical Sales Quantity by Type (2018-2024)
4.1.2 Global CINV Existing and Pipeline Drugs Forecasted Sales Quantity by Type (2024-2034)
4.1.3 Global CINV Existing and Pipeline Drugs Sales Quantity Market Share by Type (2018-2034)
4.2 Global CINV Existing and Pipeline Drugs Revenue by Type
4.2.1 Global CINV Existing and Pipeline Drugs Historical Revenue by Type (2018-2024)
4.2.2 Global CINV Existing and Pipeline Drugs Forecasted Revenue by Type (2024-2034)
4.2.3 Global CINV Existing and Pipeline Drugs Revenue Market Share by Type (2018-2034)
4.3 Global CINV Existing and Pipeline Drugs Price by Type
4.3.1 Global CINV Existing and Pipeline Drugs Price by Type (2018-2024)
4.3.2 Global CINV Existing and Pipeline Drugs Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global CINV Existing and Pipeline Drugs Sales Quantity by Application
5.1.1 Global CINV Existing and Pipeline Drugs Historical Sales Quantity by Application (2018-2024)
5.1.2 Global CINV Existing and Pipeline Drugs Forecasted Sales Quantity by Application (2024-2034)
5.1.3 Global CINV Existing and Pipeline Drugs Sales Quantity Market Share by Application (2018-2034)
5.2 Global CINV Existing and Pipeline Drugs Revenue by Application
5.2.1 Global CINV Existing and Pipeline Drugs Historical Revenue by Application (2018-2024)
5.2.2 Global CINV Existing and Pipeline Drugs Forecasted Revenue by Application (2024-2034)
5.2.3 Global CINV Existing and Pipeline Drugs Revenue Market Share by Application (2018-2034)
5.3 Global CINV Existing and Pipeline Drugs Price by Application
5.3.1 Global CINV Existing and Pipeline Drugs Price by Application (2018-2024)
5.3.2 Global CINV Existing and Pipeline Drugs Price Forecast by Application (2024-2034)
6 North America
6.1 North America CINV Existing and Pipeline Drugs Sales by Company
6.1.1 North America CINV Existing and Pipeline Drugs Revenue by Company (2018-2024)
6.1.2 North America CINV Existing and Pipeline Drugs Sales Quantity by Company (2018-2024)
6.2 North America CINV Existing and Pipeline Drugs Market Size by Type
6.2.1 North America CINV Existing and Pipeline Drugs Sales Quantity by Type (2018-2034)
6.2.2 North America CINV Existing and Pipeline Drugs Revenue by Type (2018-2034)
6.3 North America CINV Existing and Pipeline Drugs Market Size by Application
6.3.1 North America CINV Existing and Pipeline Drugs Sales Quantity by Application (2018-2034)
6.3.2 North America CINV Existing and Pipeline Drugs Revenue by Application (2018-2034)
6.4 North America CINV Existing and Pipeline Drugs Market Size by Country
6.4.1 North America CINV Existing and Pipeline Drugs Revenue by Country: 2018 VS 2022 VS 2034
6.4.2 North America CINV Existing and Pipeline Drugs Revenue by Country (2018-2034)
6.4.3 North America CINV Existing and Pipeline Drugs Sales Quantity by Country (2018-2034)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe CINV Existing and Pipeline Drugs Sales by Company
7.1.1 Europe CINV Existing and Pipeline Drugs Sales Quantity by Company (2018-2024)
7.1.2 Europe CINV Existing and Pipeline Drugs Revenue by Company (2018-2024)
7.2 Europe CINV Existing and Pipeline Drugs Market Size by Type
7.2.1 Europe CINV Existing and Pipeline Drugs Sales Quantity by Type (2018-2034)
7.2.2 Europe CINV Existing and Pipeline Drugs Revenue by Type (2018-2034)
7.3 Europe CINV Existing and Pipeline Drugs Market Size by Application
7.3.1 Europe CINV Existing and Pipeline Drugs Sales Quantity by Application (2018-2034)
7.3.2 Europe CINV Existing and Pipeline Drugs Revenue by Application (2018-2034)
7.4 Europe CINV Existing and Pipeline Drugs Market Size by Country
7.4.1 Europe CINV Existing and Pipeline Drugs Revenue by Country: 2018 VS 2022 VS 2034
7.4.2 Europe CINV Existing and Pipeline Drugs Revenue by Country (2018-2034)
7.4.3 Europe CINV Existing and Pipeline Drugs Sales Quantity by Country (2018-2034)
7.4.4 Germany
7.4.5 France
7.4.6 U.K.
7.4.7 Italy
7.4.8 Russia
8 China
8.1 China CINV Existing and Pipeline Drugs Sales by Company
8.1.1 China CINV Existing and Pipeline Drugs Sales Quantity by Company (2018-2024)
8.1.2 China CINV Existing and Pipeline Drugs Revenue by Company (2018-2024)
8.2 China CINV Existing and Pipeline Drugs Market Size by Type
8.2.1 China CINV Existing and Pipeline Drugs Sales Quantity by Type (2018-2034)
8.2.2 China CINV Existing and Pipeline Drugs Revenue by Type (2018-2034)
8.3 China CINV Existing and Pipeline Drugs Market Size by Application
8.3.1 China CINV Existing and Pipeline Drugs Sales Quantity by Application (2018-2034)
8.3.2 China CINV Existing and Pipeline Drugs Revenue by Application (2018-2034)
9 APAC (excluding China)
9.1 APAC CINV Existing and Pipeline Drugs Sales by Company
9.1.1 APAC CINV Existing and Pipeline Drugs Sales Quantity by Company (2018-2024)
9.1.2 APAC CINV Existing and Pipeline Drugs Revenue by Company (2018-2024)
9.2 APAC CINV Existing and Pipeline Drugs Market Size by Type
9.2.1 APAC CINV Existing and Pipeline Drugs Sales Quantity by Type (2018-2034)
9.2.2 APAC CINV Existing and Pipeline Drugs Revenue by Type (2018-2034)
9.3 APAC CINV Existing and Pipeline Drugs Market Size by Application
9.3.1 APAC CINV Existing and Pipeline Drugs Sales Quantity by Application (2018-2034)
9.3.2 APAC CINV Existing and Pipeline Drugs Revenue by Application (2018-2034)
9.4 APAC CINV Existing and Pipeline Drugs Market Size by Region
9.4.1 APAC CINV Existing and Pipeline Drugs Revenue by Region: 2018 VS 2022 VS 2034
9.4.2 APAC CINV Existing and Pipeline Drugs Revenue by Region (2018-2034)
9.4.3 APAC CINV Existing and Pipeline Drugs Sales Quantity by Region (2018-2034)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America CINV Existing and Pipeline Drugs Sales by Company
10.1.1 Middle East, Africa and Latin America CINV Existing and Pipeline Drugs Sales Quantity by Company (2018-2024)
10.1.2 Middle East, Africa and Latin America CINV Existing and Pipeline Drugs Revenue by Company (2018-2024)
10.2 Middle East, Africa and Latin America CINV Existing and Pipeline Drugs Market Size by Type
10.2.1 Middle East, Africa and Latin America CINV Existing and Pipeline Drugs Sales Quantity by Type (2018-2034)
10.2.2 Middle East, Africa and Latin America CINV Existing and Pipeline Drugs Revenue by Type (2018-2034)
10.3 Middle East, Africa and Latin America CINV Existing and Pipeline Drugs Market Size by Application
10.3.1 Middle East, Africa and Latin America CINV Existing and Pipeline Drugs Sales Quantity by Application (2018-2034)
10.3.2 Middle East, Africa and Latin America CINV Existing and Pipeline Drugs Revenue by Application (2018-2034)
10.4 Middle East, Africa and Latin America CINV Existing and Pipeline Drugs Market Size by Country
10.4.1 Middle East, Africa and Latin America CINV Existing and Pipeline Drugs Revenue by Country: 2018 VS 2022 VS 2034
10.4.2 Middle East, Africa and Latin America CINV Existing and Pipeline Drugs Revenue by Country (2018-2034)
10.4.3 Middle East, Africa and Latin America CINV Existing and Pipeline Drugs Sales Quantity by Country (2018-2034)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Israel
10.4.8 GCC Countries
11 Company Profiles
11.1 GlaxoSmithKline
11.1.1 GlaxoSmithKline Company Information
11.1.2 GlaxoSmithKline Overview
11.1.3 GlaxoSmithKline CINV Existing and Pipeline Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.1.4 GlaxoSmithKline CINV Existing and Pipeline Drugs Products and Services
11.1.5 GlaxoSmithKline CINV Existing and Pipeline Drugs SWOT Analysis
11.1.6 GlaxoSmithKline Recent Developments
11.2 Helsinn
11.2.1 Helsinn Company Information
11.2.2 Helsinn Overview
11.2.3 Helsinn CINV Existing and Pipeline Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.2.4 Helsinn CINV Existing and Pipeline Drugs Products and Services
11.2.5 Helsinn CINV Existing and Pipeline Drugs SWOT Analysis
11.2.6 Helsinn Recent Developments
11.3 Heron Therapeutics
11.3.1 Heron Therapeutics Company Information
11.3.2 Heron Therapeutics Overview
11.3.3 Heron Therapeutics CINV Existing and Pipeline Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.3.4 Heron Therapeutics CINV Existing and Pipeline Drugs Products and Services
11.3.5 Heron Therapeutics CINV Existing and Pipeline Drugs SWOT Analysis
11.3.6 Heron Therapeutics Recent Developments
11.4 Merck
11.4.1 Merck Company Information
11.4.2 Merck Overview
11.4.3 Merck CINV Existing and Pipeline Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.4.4 Merck CINV Existing and Pipeline Drugs Products and Services
11.4.5 Merck CINV Existing and Pipeline Drugs SWOT Analysis
11.4.6 Merck Recent Developments
11.5 Tesaro
11.5.1 Tesaro Company Information
11.5.2 Tesaro Overview
11.5.3 Tesaro CINV Existing and Pipeline Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.5.4 Tesaro CINV Existing and Pipeline Drugs Products and Services
11.5.5 Tesaro CINV Existing and Pipeline Drugs SWOT Analysis
11.5.6 Tesaro Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 CINV Existing and Pipeline Drugs Value Chain Analysis
12.2 CINV Existing and Pipeline Drugs Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 CINV Existing and Pipeline Drugs Production Mode & Process
12.4 CINV Existing and Pipeline Drugs Sales and Marketing
12.4.1 CINV Existing and Pipeline Drugs Sales Channels
12.4.2 CINV Existing and Pipeline Drugs Distributors
12.5 CINV Existing and Pipeline Drugs Customers
13 Market Dynamics
13.1 CINV Existing and Pipeline Drugs Industry Trends
13.2 CINV Existing and Pipeline Drugs Market Drivers
13.3 CINV Existing and Pipeline Drugs Market Challenges
13.4 CINV Existing and Pipeline Drugs Market Restraints
14 Key Findings
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global CINV Existing and Pipeline Drugs Market Size Growth Rate (CAGR) by Type, 2018 VS 2022 VS 2034 (US$ Million)
Table 2. Major Manufacturers of Aloxi
Table 3. Major Manufacturers of Zofran Generic
Table 4. Major Manufacturers of Kytril Generic
Table 5. Major Manufacturers of Emend
Table 6. Major Manufacturers of Akynzeo
Table 7. Major Manufacturers of SUSTOL
Table 8. Major Manufacturers of Rolapitant
Table 9. Global CINV Existing and Pipeline Drugs Market Size Growth Rate (CAGR) by Application, 2018 VS 2022 VS 2034 (US$ Million)
Table 10. Global CINV Existing and Pipeline Drugs Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 11. Global CINV Existing and Pipeline Drugs Revenue by Region (2018-2024) & (US$ Million)
Table 12. Global CINV Existing and Pipeline Drugs Revenue Market Share by Region (2018-2024)
Table 13. Global CINV Existing and Pipeline Drugs Revenue by Region (2024-2034) & (US$ Million)
Table 14. Global CINV Existing and Pipeline Drugs Revenue Market Share by Region (2024-2034)
Table 15. Global CINV Existing and Pipeline Drugs Sales Quantity by Region: 2018 VS 2022 VS 2034 (Kg)
Table 16. Global CINV Existing and Pipeline Drugs Sales by Region (2018-2024) & (Kg)
Table 17. Global CINV Existing and Pipeline Drugs Sales Market Share by Region (2018-2024)
Table 18. Global CINV Existing and Pipeline Drugs Sales by Region (2024-2034) & (Kg)
Table 19. Global CINV Existing and Pipeline Drugs Sales Market Share by Region (2024-2034)
Table 20. Global CINV Existing and Pipeline Drugs Sales Quantity by Manufacturers (2018-2024) & (Kg)
Table 21. Global CINV Existing and Pipeline Drugs Sales Quantity Share by Manufacturers (2018-2024)
Table 22. Global CINV Existing and Pipeline Drugs Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 23. Global CINV Existing and Pipeline Drugs Revenue Share by Manufacturers (2018-2024)
Table 24. Global CINV Existing and Pipeline Drugs Price by Manufacturers 2018-2024 (USD/Kg)
Table 25. Global Key Players of CINV Existing and Pipeline Drugs, Industry Ranking, 2021 VS 2022
Table 26. Global CINV Existing and Pipeline Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 27. Global CINV Existing and Pipeline Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in CINV Existing and Pipeline Drugs as of 2022)
Table 28. Global Key Manufacturers of CINV Existing and Pipeline Drugs, Manufacturing Base Distribution and Headquarters
Table 29. Global Key Manufacturers of CINV Existing and Pipeline Drugs, Product Offered and Application
Table 30. Global Key Manufacturers of CINV Existing and Pipeline Drugs, Date of Enter into This Industry
Table 31. Mergers & Acquisitions, Expansion Plans
Table 32. Global CINV Existing and Pipeline Drugs Sales Quantity by Type (2018-2024) & (Kg)
Table 33. Global CINV Existing and Pipeline Drugs Sales Quantity by Type (2024-2034) & (Kg)
Table 34. Global CINV Existing and Pipeline Drugs Sales Quantity Share by Type (2018-2024)
Table 35. Global CINV Existing and Pipeline Drugs Sales Quantity Share by Type (2024-2034)
Table 36. Global CINV Existing and Pipeline Drugs Revenue by Type (2018-2024) & (US$ Million)
Table 37. Global CINV Existing and Pipeline Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 38. Global CINV Existing and Pipeline Drugs Revenue Share by Type (2018-2024)
Table 39. Global CINV Existing and Pipeline Drugs Revenue Share by Type (2024-2034)
Table 40. CINV Existing and Pipeline Drugs Price by Type (2018-2024) & (USD/Kg)
Table 41. Global CINV Existing and Pipeline Drugs Price Forecast by Type (2024-2034) & (USD/Kg)
Table 42. Global CINV Existing and Pipeline Drugs Sales Quantity by Application (2018-2024) & (Kg)
Table 43. Global CINV Existing and Pipeline Drugs Sales Quantity by Application (2024-2034) & (Kg)
Table 44. Global CINV Existing and Pipeline Drugs Sales Quantity Share by Application (2018-2024)
Table 45. Global CINV Existing and Pipeline Drugs Sales Quantity Share by Application (2024-2034)
Table 46. Global CINV Existing and Pipeline Drugs Revenue by Application (2018-2024) & (US$ Million)
Table 47. Global CINV Existing and Pipeline Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 48. Global CINV Existing and Pipeline Drugs Revenue Share by Application (2018-2024)
Table 49. Global CINV Existing and Pipeline Drugs Revenue Share by Application (2024-2034)
Table 50. CINV Existing and Pipeline Drugs Price by Application (2018-2024) & (USD/Kg)
Table 51. Global CINV Existing and Pipeline Drugs Price Forecast by Application (2024-2034) & (USD/Kg)
Table 52. North America CINV Existing and Pipeline Drugs Revenue by Company (2018-2024) & (US$ Million)
Table 53. North America CINV Existing and Pipeline Drugs Sales Quantity by Company (2018-2024) & (Kg)
Table 54. North America CINV Existing and Pipeline Drugs Sales Quantity by Type (2018-2024) & (Kg)
Table 55. North America CINV Existing and Pipeline Drugs Sales Quantity by Type (2024-2034) & (Kg)
Table 56. North America CINV Existing and Pipeline Drugs Revenue by Type (2018-2024) & (US$ Million)
Table 57. North America CINV Existing and Pipeline Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 58. North America CINV Existing and Pipeline Drugs Sales Quantity by Application (2018-2024) & (Kg)
Table 59. North America CINV Existing and Pipeline Drugs Sales Quantity by Application (2024-2034) & (Kg)
Table 60. North America CINV Existing and Pipeline Drugs Revenue by Application (2018-2024) & (US$ Million)
Table 61. North America CINV Existing and Pipeline Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 62. North America CINV Existing and Pipeline Drugs Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 63. North America CINV Existing and Pipeline Drugs Revenue by Country (2018-2024) & (US$ Million)
Table 64. North America CINV Existing and Pipeline Drugs Revenue by Country (2024-2034) & (US$ Million)
Table 65. North America CINV Existing and Pipeline Drugs Sales Quantity by Country (2018-2024) & (Kg)
Table 66. North America CINV Existing and Pipeline Drugs Sales Quantity by Country (2024-2034) & (Kg)
Table 67. Europe CINV Existing and Pipeline Drugs Sales Quantity by Company (2018-2024) & (Kg)
Table 68. Europe CINV Existing and Pipeline Drugs Revenue by Company (2018-2024) & (US$ Million)
Table 69. Europe CINV Existing and Pipeline Drugs Sales Quantity by Type (2018-2024) & (Kg)
Table 70. Europe CINV Existing and Pipeline Drugs Sales Quantity by Type (2024-2034) & (Kg)
Table 71. Europe CINV Existing and Pipeline Drugs Revenue by Type (2018-2024) & (US$ Million)
Table 72. Europe CINV Existing and Pipeline Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 73. Europe CINV Existing and Pipeline Drugs Sales Quantity by Application (2018-2024) & (Kg)
Table 74. Europe CINV Existing and Pipeline Drugs Sales Quantity by Application (2024-2034) & (Kg)
Table 75. Europe CINV Existing and Pipeline Drugs Revenue by Application (2018-2024) & (US$ Million)
Table 76. Europe CINV Existing and Pipeline Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 77. Europe CINV Existing and Pipeline Drugs Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 78. Europe CINV Existing and Pipeline Drugs Revenue by Country (2018-2024) & (US$ Million)
Table 79. Europe CINV Existing and Pipeline Drugs Revenue by Country (2024-2034) & (US$ Million)
Table 80. Europe CINV Existing and Pipeline Drugs Sales Quantity by Country (2018-2024) & (Kg)
Table 81. Europe CINV Existing and Pipeline Drugs Sales Quantity by Country (2024-2034) & (Kg)
Table 82. China CINV Existing and Pipeline Drugs Sales Quantity by Company (2018-2024) & (Kg)
Table 83. China CINV Existing and Pipeline Drugs Revenue by Company (2018-2024) & (US$ Million)
Table 84. China CINV Existing and Pipeline Drugs Sales Quantity by Type (2018-2024) & (Kg)
Table 85. China CINV Existing and Pipeline Drugs Sales Quantity by Type (2024-2034) & (Kg)
Table 86. China CINV Existing and Pipeline Drugs Revenue by Type (2018-2024) & (US$ Million)
Table 87. China CINV Existing and Pipeline Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 88. China CINV Existing and Pipeline Drugs Sales Quantity by Application (2018-2024) & (Kg)
Table 89. China CINV Existing and Pipeline Drugs Sales Quantity by Application (2024-2034) & (Kg)
Table 90. China CINV Existing and Pipeline Drugs Revenue by Application (2018-2024) & (US$ Million)
Table 91. China CINV Existing and Pipeline Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 92. APAC CINV Existing and Pipeline Drugs Sales Quantity by Company (2018-2024) & (Kg)
Table 93. APAC CINV Existing and Pipeline Drugs Revenue by Company (2018-2024) & (US$ Million)
Table 94. APAC CINV Existing and Pipeline Drugs Sales Quantity by Type (2018-2024) & (Kg)
Table 95. APAC CINV Existing and Pipeline Drugs Sales Quantity by Type (2024-2034) & (Kg)
Table 96. APAC CINV Existing and Pipeline Drugs Revenue by Type (2018-2024) & (US$ Million)
Table 97. APAC CINV Existing and Pipeline Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 98. APAC CINV Existing and Pipeline Drugs Sales Quantity by Application (2018-2024) & (Kg)
Table 99. APAC CINV Existing and Pipeline Drugs Sales Quantity by Application (2024-2034) & (Kg)
Table 100. APAC CINV Existing and Pipeline Drugs Revenue by Application (2018-2024) & (US$ Million)
Table 101. APAC CINV Existing and Pipeline Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 102. APAC CINV Existing and Pipeline Drugs Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 103. APAC CINV Existing and Pipeline Drugs Revenue by Region (2018-2024) & (US$ Million)
Table 104. APAC CINV Existing and Pipeline Drugs Revenue by Region (2024-2034) & (US$ Million)
Table 105. APAC CINV Existing and Pipeline Drugs Sales Quantity by Region (2018-2024) & (Kg)
Table 106. APAC CINV Existing and Pipeline Drugs Sales Quantity by Region (2024-2034) & (Kg)
Table 107. Middle East, Africa and Latin America CINV Existing and Pipeline Drugs Sales Quantity by Company (2018-2024) & (Kg)
Table 108. Middle East, Africa and Latin America CINV Existing and Pipeline Drugs Revenue by Company (2018-2024) & (US$ Million)
Table 109. Middle East, Africa and Latin America CINV Existing and Pipeline Drugs Sales Quantity by Type (2018-2024) & (Kg)
Table 110. Middle East, Africa and Latin America CINV Existing and Pipeline Drugs Sales Quantity by Type (2024-2034) & (Kg)
Table 111. Middle East, Africa and Latin America CINV Existing and Pipeline Drugs Revenue by Type (2018-2024) & (US$ Million)
Table 112. Middle East, Africa and Latin America CINV Existing and Pipeline Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 113. Middle East, Africa and Latin America CINV Existing and Pipeline Drugs Sales Quantity by Application (2018-2024) & (Kg)
Table 114. Middle East, Africa and Latin America CINV Existing and Pipeline Drugs Sales Quantity by Application (2024-2034) & (Kg)
Table 115. Middle East, Africa and Latin America CINV Existing and Pipeline Drugs Revenue by Application (2018-2024) & (US$ Million)
Table 116. Middle East, Africa and Latin America CINV Existing and Pipeline Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 117. Middle East, Africa and Latin America CINV Existing and Pipeline Drugs Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 118. Middle East, Africa and Latin America CINV Existing and Pipeline Drugs Revenue by Country (2018-2024) & (US$ Million)
Table 119. Middle East, Africa and Latin America CINV Existing and Pipeline Drugs Revenue by Country (2024-2034) & (US$ Million)
Table 120. Middle East, Africa and Latin America CINV Existing and Pipeline Drugs Sales Quantity by Country (2018-2024) & (Kg)
Table 121. Middle East, Africa and Latin America CINV Existing and Pipeline Drugs Sales Quantity by Country (2024-2034) & (Kg)
Table 122. GlaxoSmithKline Company Information
Table 123. GlaxoSmithKline Description and Overview
Table 124. GlaxoSmithKline CINV Existing and Pipeline Drugs Sales Quantity (Kg), Revenue (US$ Million), Average Selling Price (ASP) (USD/Kg) and Gross Margin (2018-2024)
Table 125. GlaxoSmithKline CINV Existing and Pipeline Drugs Product and Services
Table 126. GlaxoSmithKline CINV Existing and Pipeline Drugs SWOT Analysis
Table 127. GlaxoSmithKline Recent Developments
Table 128. Helsinn Company Information
Table 129. Helsinn Description and Overview
Table 130. Helsinn CINV Existing and Pipeline Drugs Sales Quantity (Kg), Revenue (US$ Million), Average Selling Price (ASP) (USD/Kg) and Gross Margin (2018-2024)
Table 131. Helsinn CINV Existing and Pipeline Drugs Product and Services
Table 132. Helsinn CINV Existing and Pipeline Drugs SWOT Analysis
Table 133. Helsinn Recent Developments
Table 134. Heron Therapeutics Company Information
Table 135. Heron Therapeutics Description and Overview
Table 136. Heron Therapeutics CINV Existing and Pipeline Drugs Sales Quantity (Kg), Revenue (US$ Million), Average Selling Price (ASP) (USD/Kg) and Gross Margin (2018-2024)
Table 137. Heron Therapeutics CINV Existing and Pipeline Drugs Product and Services
Table 138. Heron Therapeutics CINV Existing and Pipeline Drugs SWOT Analysis
Table 139. Heron Therapeutics Recent Developments
Table 140. Merck Company Information
Table 141. Merck Description and Overview
Table 142. Merck CINV Existing and Pipeline Drugs Sales Quantity (Kg), Revenue (US$ Million), Average Selling Price (ASP) (USD/Kg) and Gross Margin (2018-2024)
Table 143. Merck CINV Existing and Pipeline Drugs Product and Services
Table 144. Merck CINV Existing and Pipeline Drugs SWOT Analysis
Table 145. Merck Recent Developments
Table 146. Tesaro Company Information
Table 147. Tesaro Description and Overview
Table 148. Tesaro CINV Existing and Pipeline Drugs Sales Quantity (Kg), Revenue (US$ Million), Average Selling Price (ASP) (USD/Kg) and Gross Margin (2018-2024)
Table 149. Tesaro CINV Existing and Pipeline Drugs Product and Services
Table 150. Tesaro CINV Existing and Pipeline Drugs SWOT Analysis
Table 151. Tesaro Recent Developments
Table 152. Key Raw Materials Lists
Table 153. Raw Materials Key Suppliers Lists
Table 154. CINV Existing and Pipeline Drugs Distributors List
Table 155. CINV Existing and Pipeline Drugs Customers List
Table 156. CINV Existing and Pipeline Drugs Market Trends
Table 157. CINV Existing and Pipeline Drugs Market Drivers
Table 158. CINV Existing and Pipeline Drugs Market Challenges
Table 159. CINV Existing and Pipeline Drugs Market Restraints
Table 160. Research Programs/Design for This Report
Table 161. Key Data Information from Secondary Sources
Table 162. Key Data Information from Primary Sources
List of Figures
Figure 1. CINV Existing and Pipeline Drugs Product Picture
Figure 2. Global CINV Existing and Pipeline Drugs Market Size Growth Rate by Type, 2018 VS 2022 VS 2034 (US$ Million)
Figure 3. Global CINV Existing and Pipeline Drugs Market Share by Type in 2022 & 2034
Figure 4. Aloxi Product Picture
Figure 5. Zofran Generic Product Picture
Figure 6. Kytril Generic Product Picture
Figure 7. Emend Product Picture
Figure 8. Akynzeo Product Picture
Figure 9. SUSTOL Product Picture
Figure 10. Rolapitant Product Picture
Figure 11. Global CINV Existing and Pipeline Drugs Market Size Growth Rate by Application, 2018 VS 2022 VS 2034 (US$ Million)
Figure 12. Global CINV Existing and Pipeline Drugs Market Share by Application in 2022 & 2034
Figure 13. Hospitals
Figure 14. Specialty Clinics
Figure 15. Diagnostic Centers Therapeutics
Figure 16. Hospital Pharmacies
Figure 17. Drugstores
Figure 18. CINV Existing and Pipeline Drugs Report Years Considered
Figure 19. Global CINV Existing and Pipeline Drugs Revenue, (US$ Million), 2018 VS 2022 VS 2034
Figure 20. Global CINV Existing and Pipeline Drugs Revenue 2018-2034 (US$ Million)
Figure 21. Global CINV Existing and Pipeline Drugs Revenue Market Share by Region in Percentage: 2022 Versus 2034
Figure 22. Global CINV Existing and Pipeline Drugs Sales Quantity 2018-2034 (Kg)
Figure 23. Global CINV Existing and Pipeline Drugs Sales Quantity Market Share by Region (2018-2024)
Figure 24. Global CINV Existing and Pipeline Drugs Sales Quantity Market Share by Region (2024-2034)
Figure 25. North America CINV Existing and Pipeline Drugs Sales Quantity YoY (2018-2034) & (Kg)
Figure 26. North America CINV Existing and Pipeline Drugs Revenue YoY (2018-2034) & (US$ Million)
Figure 27. Europe CINV Existing and Pipeline Drugs Sales Quantity YoY (2018-2034) & (Kg)
Figure 28. Europe CINV Existing and Pipeline Drugs Revenue YoY (2018-2034) & (US$ Million)
Figure 29. China CINV Existing and Pipeline Drugs Sales Quantity YoY (2018-2034) & (Kg)
Figure 30. China CINV Existing and Pipeline Drugs Revenue YoY (2018-2034) & (US$ Million)
Figure 31. APAC CINV Existing and Pipeline Drugs Sales Quantity YoY (2018-2034) & (Kg)
Figure 32. APAC CINV Existing and Pipeline Drugs Revenue YoY (2018-2034) & (US$ Million)
Figure 33. Middle East, Africa and Latin America CINV Existing and Pipeline Drugs Sales Quantity YoY (2018-2034) & (Kg)
Figure 34. Middle East, Africa and Latin America CINV Existing and Pipeline Drugs Revenue YoY (2018-2034) & (US$ Million)
Figure 35. The Top 10 and Top 5 Players Market Share by CINV Existing and Pipeline Drugs Sales Quantity in 2022
Figure 36. The Top 10 and Top 5 Players Market Share by CINV Existing and Pipeline Drugs Revenue in 2022
Figure 37. CINV Existing and Pipeline Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 38. Global CINV Existing and Pipeline Drugs Sales Quantity Market Share by Type (2018-2034)
Figure 39. Global CINV Existing and Pipeline Drugs Revenue Market Share by Type (2018-2034)
Figure 40. Global CINV Existing and Pipeline Drugs Sales Quantity Market Share by Application (2018-2034)
Figure 41. Global CINV Existing and Pipeline Drugs Revenue Market Share by Application (2018-2034)
Figure 42. North America CINV Existing and Pipeline Drugs Revenue Market Share by Company in 2022
Figure 43. North America CINV Existing and Pipeline Drugs Sales Quantity Market Share by Company in 2022
Figure 44. North America CINV Existing and Pipeline Drugs Sales Quantity Market Share by Type (2018-2034)
Figure 45. North America CINV Existing and Pipeline Drugs Revenue Market Share by Type (2018-2034)
Figure 46. North America CINV Existing and Pipeline Drugs Sales Quantity Market Share by Application (2018-2034)
Figure 47. North America CINV Existing and Pipeline Drugs Revenue Market Share by Application (2018-2034)
Figure 48. North America CINV Existing and Pipeline Drugs Revenue Share by Country (2018-2034)
Figure 49. North America CINV Existing and Pipeline Drugs Sales Quantity Share by Country (2018-2034)
Figure 50. U.S. CINV Existing and Pipeline Drugs Revenue (2018-2034) & (US$ Million)
Figure 51. Canada CINV Existing and Pipeline Drugs Revenue (2018-2034) & (US$ Million)
Figure 52. Europe CINV Existing and Pipeline Drugs Sales Quantity Market Share by Company in 2022
Figure 53. Europe CINV Existing and Pipeline Drugs Revenue Market Share by Company in 2022
Figure 54. Europe CINV Existing and Pipeline Drugs Sales Quantity Market Share by Type (2018-2034)
Figure 55. Europe CINV Existing and Pipeline Drugs Revenue Market Share by Type (2018-2034)
Figure 56. Europe CINV Existing and Pipeline Drugs Sales Quantity Market Share by Application (2018-2034)
Figure 57. Europe CINV Existing and Pipeline Drugs Revenue Market Share by Application (2018-2034)
Figure 58. Europe CINV Existing and Pipeline Drugs Revenue Share by Country (2018-2034)
Figure 59. Europe CINV Existing and Pipeline Drugs Sales Quantity Share by Country (2018-2034)
Figure 60. Germany CINV Existing and Pipeline Drugs Revenue (2018-2034) & (US$ Million)
Figure 61. France CINV Existing and Pipeline Drugs Revenue (2018-2034) & (US$ Million)
Figure 62. U.K. CINV Existing and Pipeline Drugs Revenue (2018-2034) & (US$ Million)
Figure 63. Italy CINV Existing and Pipeline Drugs Revenue (2018-2034) & (US$ Million)
Figure 64. Russia CINV Existing and Pipeline Drugs Revenue (2018-2034) & (US$ Million)
Figure 65. China CINV Existing and Pipeline Drugs Sales Quantity Market Share by Company in 2022
Figure 66. China CINV Existing and Pipeline Drugs Revenue Market Share by Company in 2022
Figure 67. China CINV Existing and Pipeline Drugs Sales Quantity Market Share by Type (2018-2034)
Figure 68. China CINV Existing and Pipeline Drugs Revenue Market Share by Type (2018-2034)
Figure 69. China CINV Existing and Pipeline Drugs Sales Quantity Market Share by Application (2018-2034)
Figure 70. China CINV Existing and Pipeline Drugs Revenue Market Share by Application (2018-2034)
Figure 71. APAC CINV Existing and Pipeline Drugs Sales Quantity Market Share by Company in 2022
Figure 72. APAC CINV Existing and Pipeline Drugs Revenue Market Share by Company in 2022
Figure 73. APAC CINV Existing and Pipeline Drugs Sales Quantity Market Share by Type (2018-2034)
Figure 74. APAC CINV Existing and Pipeline Drugs Revenue Market Share by Type (2018-2034)
Figure 75. APAC CINV Existing and Pipeline Drugs Sales Quantity Market Share by Application (2018-2034)
Figure 76. APAC CINV Existing and Pipeline Drugs Revenue Market Share by Application (2018-2034)
Figure 77. APAC CINV Existing and Pipeline Drugs Revenue Share by Region (2018-2034)
Figure 78. APAC CINV Existing and Pipeline Drugs Sales Quantity Share by Region (2018-2034)
Figure 79. Japan CINV Existing and Pipeline Drugs Revenue (2018-2034) & (US$ Million)
Figure 80. South Korea CINV Existing and Pipeline Drugs Revenue (2018-2034) & (US$ Million)
Figure 81. China Taiwan CINV Existing and Pipeline Drugs Revenue (2018-2034) & (US$ Million)
Figure 82. Southeast Asia CINV Existing and Pipeline Drugs Revenue (2018-2034) & (US$ Million)
Figure 83. India CINV Existing and Pipeline Drugs Revenue (2018-2034) & (US$ Million)
Figure 84. Middle East, Africa and Latin America CINV Existing and Pipeline Drugs Sales Quantity Market Share by Company in 2022
Figure 85. Middle East, Africa and Latin America CINV Existing and Pipeline Drugs Revenue Market Share by Company in 2022
Figure 86. Middle East, Africa and Latin America CINV Existing and Pipeline Drugs Sales Quantity Market Share by Type (2018-2034)
Figure 87. Middle East, Africa and Latin America CINV Existing and Pipeline Drugs Revenue Market Share by Type (2018-2034)
Figure 88. Middle East, Africa and Latin America CINV Existing and Pipeline Drugs Sales Quantity Market Share by Application (2018-2034)
Figure 89. Middle East, Africa and Latin America CINV Existing and Pipeline Drugs Revenue Market Share by Application (2018-2034)
Figure 90. Middle East, Africa and Latin America CINV Existing and Pipeline Drugs Sales Quantity Share by Country (2018-2034)
Figure 91. Middle East, Africa and Latin America CINV Existing and Pipeline Drugs Revenue Share by Country (2018-2034)
Figure 92. Brazil CINV Existing and Pipeline Drugs Revenue (2018-2034) & (US$ Million)
Figure 93. Mexico CINV Existing and Pipeline Drugs Revenue (2018-2034) & (US$ Million)
Figure 94. Turkey CINV Existing and Pipeline Drugs Revenue (2018-2034) & (US$ Million)
Figure 95. Israel CINV Existing and Pipeline Drugs Revenue (2018-2034) & (US$ Million)
Figure 96. GCC Countries CINV Existing and Pipeline Drugs Revenue (2018-2034) & (US$ Million)
Figure 97. CINV Existing and Pipeline Drugs Value Chain
Figure 98. CINV Existing and Pipeline Drugs Production Process
Figure 99. Channels of Distribution (Direct Vs Distribution)
Figure 100. Distributors Profiles
Figure 101. Bottom-up and Top-down Approaches for This Report
Figure 102. Data Triangulation
Figure 103. Key Executives Interviewed